MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Paris:ALTHE) (Alternext, FR0010120402 - ALTHE, PEA PME eligible), a company specialized in cutting-edge medical equipment for echotherapy, announced the publication of an asian study demonstrating that echotherapy using Echopulse® significantly reduces the size of large benign thyroid nodules. The study, entitled “Single-session high intensity focus ultrasound (HIFU) treatment in large-sized benign thyroid nodules” was published online on March 2, 2017 in the American Thyroid Association (ATA)’s official peer-reviewed journal, Thyroid.
The open-label, 73-patient study evaluated the efficacy of a single treatment of ultrasound-guided HIFU ablation employing the Echopulse® echotherapy system to treat small to large-sized benign thyroid nodules. Patients were divided into three groups depending on nodule size: small nodules <10 mL (Group 1), medium nodules between 10-30 mL (Group 2) and large nodules >30 mL (Group 3). The primary endpoint was nodule volume at six months with ablation success defined as more than a 50% reduction in nodule volume. Overall median volume reduction at six months was 68.3%. The treatment was well-tolerated with no reported serious side effects.
Professor Brian Lang, MD, The University of Hong Kong and principal investigator of this study, commented: “This study demonstrated that echotherapy is effective and safe on a wide range of predominantly-solid benign thyroid nodules with encouraging volume reductions at six months. These results demonstrated a very feasible alternative to conventional thyroid surgery, with significant reduction in nodule volume after just single-session treatment.”
David Caumartin, CEO of Theraclion added: “The size and density of the nodule has historically limited the effectiveness of echotherapy treatment. However, the BEAMOTION software introduced in early 2016 has enabled a much faster and focused treatment, making it possible to effectively treat large nodules. This is the first publication that provides the scientific evidence that echotherapy treats small-to-large thyroid nodules”.
“It is also the first publication on an Asian population, a geography, with China and Korea at the forefront, that we anticipate will be one of our biggest market in the near future,” concluded Sylvain Yon, Deputy CEO, Theraclion.
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com
Theraclion is listed on Alternext Paris
Mnemonic: ALTHE - ISIN Code: FR0010120402